Literature DB >> 23046672

Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I.

Julien Calderaro1, Philippe Labrune, Guillaume Morcrette, Sandra Rebouissou, Dominique Franco, Sophie Prévot, Alberto Quaglia, Pierre Bedossa, Louis Libbrecht, Luigi Terracciano, G Peter A Smit, Paulette Bioulac-Sage, Jessica Zucman-Rossi.   

Abstract

BACKGROUND & AIMS: Hepatocellular adenomas (HCA) are benign liver tumors mainly related to oral contraception and classified into 4 molecular subgroups: inflammatory (IHCA), HNF1A-inactivated (H-HCA), β-catenin-activated (bHCA) or unclassified (UHCA). Glycogen storage disease type I (GSD) is a rare hereditary metabolic disease that predisposes to HCA development. The aim of our study was to characterize the molecular profile of GSD-associated HCA.
METHODS: We characterized a series of 25 HCAs developed in 15 patients with GSD by gene expression and DNA sequence of HNF1A, CTNNB1, IL6ST, GNAS, and STAT3 genes. Moreover, we searched for glycolysis, gluconeogenesis, and fatty acid synthesis alterations in GSD non-tumor livers and compared our results to those observed in a series of sporadic H-HCA and various non-GSD liver samples.
RESULTS: GSD adenomas were classified as IHCA (52%) mutated for IL6ST or GNAS, bHCA (28%) or UHCA (20%). In contrast, no HNF1A inactivation was observed, showing a different molecular subtype distribution in GSD-associated HCA from that observed in sporadic HCA (p = 0.0008). In non-tumor GSD liver samples, we identified glycolysis and fatty acid synthesis activation with gluconeogenesis repression. Interestingly, this gene expression profile was similar to that observed in sporadic H-HCA.
CONCLUSIONS: Our study showed a particular molecular profile in GSD-related HCA characterized by a lack of HNF1A inactivation. This exclusion could be explained by similar metabolic defects observed with HNF1A inactivation and glucose-6-phosphatase deficiency. Inversely, the high frequency of β-catenin mutations could be related to the increased frequency of malignant transformation in hepatocellular carcinoma.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046672     DOI: 10.1016/j.jhep.2012.09.030

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  47 in total

1.  YAP suppresses gluconeogenic gene expression through PGC1α.

Authors:  Yue Hu; Dong-Ju Shin; Hui Pan; Zhiqiang Lin; Jonathan M Dreyfuss; Fernando D Camargo; Ji Miao; Sudha B Biddinger
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

2.  Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit.

Authors:  Nicola de'Angelis; Riccardo Memeo; Julien Calderaro; Emanuele Felli; Chady Salloum; Philippe Compagnon; Alain Luciani; Alexis Laurent; Daniel Cherqui; Daniel Azoulay
Journal:  HPB (Oxford)       Date:  2014-05-23       Impact factor: 3.647

3.  Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: a potential utility as biomarkers.

Authors:  Li-Ya Chiu; Priya S Kishnani; Tzu-Po Chuang; Cheng-Yang Tang; Cheng-Yuan Liu; Deeksha Bali; Dwight Koeberl; Stephanie Austin; Keri Boyette; David A Weinstein; Elaine Murphy; Adam Yao; Yuan-Tsong Chen; Ling-Hui Li
Journal:  J Gastroenterol       Date:  2013-10-16       Impact factor: 7.527

Review 4.  Hepatocellular adenoma management: advances but still a long way to go.

Authors:  Jean Frédéric Blanc; Nora Frulio; Laurence Chiche; Paulette Bioulac-Sage; Charles Balabaud
Journal:  Hepat Oncol       Date:  2015-05-15

Review 5.  Targeting glycogen metabolism in bladder cancer.

Authors:  Carolyn Ritterson Lew; Sunny Guin; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2015-05-26       Impact factor: 14.432

6.  Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.

Authors:  Julien Calderaro; Jean C Nault; Charles Balabaud; Gabrielle Couchy; Marie-Christine Saint-Paul; Daniel Azoulay; Dalila Mehdaoui; Alain Luciani; Elie S Zafrani; Paulette Bioulac-Sage; Jessica Zucman-Rossi
Journal:  Mod Pathol       Date:  2015-10-30       Impact factor: 7.842

Review 7.  Malignant transformation of hepatocellular adenoma.

Authors:  Christine Sempoux; Charles Balabaud; Paulette Bioulac-Sage
Journal:  Hepat Oncol       Date:  2014-12-11

8.  Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.

Authors:  Goo-Young Kim; Young Mok Lee; Joon Hyun Kwon; Jun-Ho Cho; Chi-Jiunn Pan; Matthew F Starost; Brian C Mansfield; Janice Y Chou
Journal:  Mol Genet Metab       Date:  2017-01-10       Impact factor: 4.797

9.  Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.

Authors:  Steffen Durinck; Eric W Stawiski; Andrea Pavía-Jiménez; Zora Modrusan; Payal Kapur; Bijay S Jaiswal; Na Zhang; Vanina Toffessi-Tcheuyap; Thong T Nguyen; Kanika Bajaj Pahuja; Ying-Jiun Chen; Sadia Saleem; Subhra Chaudhuri; Sherry Heldens; Marlena Jackson; Samuel Peña-Llopis; Joseph Guillory; Karen Toy; Connie Ha; Corissa J Harris; Eboni Holloman; Haley M Hill; Jeremy Stinson; Celina Sanchez Rivers; Vasantharajan Janakiraman; Weiru Wang; Lisa N Kinch; Nick V Grishin; Peter M Haverty; Bernard Chow; Julian S Gehring; Jens Reeder; Gregoire Pau; Thomas D Wu; Vitaly Margulis; Yair Lotan; Arthur Sagalowsky; Ivan Pedrosa; Frederic J de Sauvage; James Brugarolas; Somasekar Seshagiri
Journal:  Nat Genet       Date:  2014-11-17       Impact factor: 38.330

10.  Recent development and gene therapy for glycogen storage disease type Ia.

Authors:  Janice Y Chou; Goo-Young Kim; Jun-Ho Cho
Journal:  Liver Res       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.